Richmond Pharmacology is delighted with the acknowledgement and features at 96 in the list of 200.

The report is the first of its kind and refers to the high-growth companies founded or led by women or have management teams that are at least 50% women.

Richmond Pharmacology qualifies for the list as it was co-founded by Medical Director Dr Ulrike Lorch and has equal representation in senior management roles throughout the business.

J.P. Morgan Private Bank's list of the top 200 female-powered businesses showcases private UK businesses that have grown sales, headcount or valuation at exceptional rates. To be eligible, companies must have grown at least one of these metrics and observed this growth in the 12 months prior to 31 October 2020. In total, it analyses the 6,085 high growth companies in the UK which meet the criteria.

Dr Ulrike Lorch commenting on the success, said, "We are delighted that Richmond Pharmacology has been recognised as one of the top high-growth companies where women form a significant proportion of the founder and leadership teams. It has been a rewarding journey from founding the company to where we are now: an innovative and highly specialised team of people who play an essential part in the development of new medicines. Men and women have always had equal roles at Richmond Pharmacology - from entry positions to the boardroom - and we share our success as a collective."

Richmond Pharmacology is proud of our diverse and inclusive culture. Currently, women contribute to over half of the collective workforce. Learn more about the JP Morgan Top 200 Female Powered Businesses. Download the report here.

Latest news

Richmond enrols first patients in Verve Therapeutic’s Heart-2 trial - pioneering a new approach to cardiovascular disease

June 27, 2024
Richmond enrols and doses the first patient in a clinical trial aimed at transforming the care of cardiovascular disease with single treatment gene-editing medicines.
Read more

A first of a kind trial in the fight against malaria

June 12, 2024
Richmond successfully recruits and enrols adults of sub-Saharan ancestry who all complete a first of its kind trial in the treatment of malaria.
Read more

Events

AHA Hypertension Scientific Sessions 2024

5 - 8 September 2024
Dr. Jörg Taubel, CEO of Richmond Pharmacology, will be attending the Hypertension 2024 Scientific Sessions
View event